TPP1 Gene - Tripeptidyl Peptidase 1

TPP1 Gene

Introduction

Tpp1 Gene Tripeptidyl Peptidase 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

{{- <!-- TPP1 Gene Page - Tripeptidyl Peptidase 1 --> -}} [@markham2017]

<div class="infobox infobox-gene"> [@kohan2015]

| Attribute | Value | [@miller2023]
|-----------|-------|
| Gene Symbol | TPP1 |
| Gene Name | Tripeptidyl Peptidase 1 |
| Official Full Name | Tripeptidyl Peptidase 1 |
| Chromosomal Location | 11p15.4 |
| GRCh38 Coordinates | chr11:2,653,227-2,660,457 |
| NCBI Gene ID | 1201 |
| OMIM ID | 607998 |
| Ensembl ID | ENSG00000142149 |
| UniProt ID | O14773 |
| Gene Family | S9 family serine proteases |

</div>}

Overview

TPP1 Gene

Introduction

Tpp1 Gene Tripeptidyl Peptidase 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

{{- <!-- TPP1 Gene Page - Tripeptidyl Peptidase 1 --> -}} [@markham2017]

<div class="infobox infobox-gene"> [@kohan2015]

| Attribute | Value | [@miller2023]
|-----------|-------|
| Gene Symbol | TPP1 |
| Gene Name | Tripeptidyl Peptidase 1 |
| Official Full Name | Tripeptidyl Peptidase 1 |
| Chromosomal Location | 11p15.4 |
| GRCh38 Coordinates | chr11:2,653,227-2,660,457 |
| NCBI Gene ID | 1201 |
| OMIM ID | 607998 |
| Ensembl ID | ENSG00000142149 |
| UniProt ID | O14773 |
| Gene Family | S9 family serine proteases |

</div>}

Overview

The TPP1 gene encodes tripeptidyl peptidase 1 (TPP1), a lysosomal serine protease that cleaves tripeptides from the N-terminus of proteins. This enzyme is essential for the degradation of proteins within lysosomes. Mutations in TPP1 cause Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), also known as Batten disease variant^[1].

Function

Enzymatic Activity

TPP1 is a 563-amino acid glycoprotein (59 kDa) that functions as a homodimer in the lysosome. It displays tripeptidyl-peptidase activity, cleaving N-terminal tripeptides from various substrates^[1].

Normal Physiological Roles

• Lysosomal Protein Degradation: Primary exopeptidase in lysosomes
• Protein Turnover: Essential for cellular protein homeostasis
• Neuronal Function: Critical for neuronal health
• [Autophagy](/entities/autophagy): Participates in protein clearance pathways

Molecular Interactions

TPP1 interacts with:

• Cathepsin proteases - Degradation pathway partners
• Lysosomal membrane proteins - Targeting and activation
• Substrate proteins - Target for degradation

Disease Associations

Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)

TPP1 mutations cause LINCL, characterized by^[1]:

| Feature | Onset | Progression |
|---------|-------|-------------|
| Seizures | 2-4 years | Myoclonic, generalized |
| Vision loss | 2-4 years | Progressive, blindness |
| Cognitive decline | 2-4 years | Rapid regression |
| Motor dysfunction | 3-5 years | Ataxia, spasticity |
| Speech loss | 3-5 years | Progressive |
| Death | 6-15 years | Variable |

Common Mutations

| Mutation | Type | Frequency | Effect |
|----------|------|-----------|--------|
| p.R127X | Nonsense | 30% | No enzyme activity |
| p.A282P | Missense | 15% | Severely reduced |
| p.D283G | Missense | 10% | Reduced activity |
| p.G437S | Missense | 8% | Partial activity |
| p.T75P | Missense | 5% | No activity |

Genotype-Phenotype Correlations

• Null/Null: Classic LINCL
• Missense/Missense: Variable, can be milder
• Compound heterozygous: Variable presentation

Expression Patterns

• Tissue Distribution: High expression in brain, retina, liver, kidney
• Brain Regions: [Cortex](/brain-regions/cortex), cerebellum, basal ganglia
• Cellular Localization: Lysosomal lumen
• Developmental Expression: Increases with age in brain
• Transcript: 1.8 kb mRNA, 13 exons

Therapeutic Approaches

Current Treatments

• Anticonvulsants: Seizure management
• Supportive care: Multidisciplinary support
• Physical/occupational therapy: Maintain function

FDA-Approved Therapy

• Cerliponase alfa (Brineura): Recombinant human TPP1 (rhTPP1) delivered via intracerebroventricular infusion. First disease-modifying therapy for LINCL^[2].

Experimental Therapies

• Gene therapy: AAV-vector delivery in clinical trials
• Stem cell therapy: Investigational approaches
• Small molecule chaperones: Being studied

Research Directions

Background

The study of Tpp1 Gene Tripeptidyl Peptidase 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis)
• [Batten Disease](/diseases/batten-disease)
• Late Infantile NCL
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)

Pathway Diagram

The following diagram shows the key molecular relationships involving TPP1 Gene - Tripeptidyl Peptidase 1 discovered through SciDEX knowledge graph analysis: